Is this all you can come up with after the discussion within the damage control group?
The main point here is not about share price appreciation and succession of drug.
The main thing here is if the cap raise double the share on issued and BOD granted more shares on that basis. Then, whatever wet dream you are having billion dollars addressable market is none of your business if you know how the market works.
How tight or loose the shares being held are decided by the BOD and obviously the value propositions.
IMHO, if you want to get breakeven or earning bags on the back of great results, you need a seriously deep pocket to keep buying. I am saying hundreds of thousands USD.
Last and most important thing is, there is no guaranteed on the trials will be success and this year raise will get them to where they want to be. So multiple raise could be possible.
- Forums
- ASX - By Stock
- IHL
- General discussion
General discussion, page-19975
-
- There are more pages in this discussion • 206 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CC9
CHARIOT CORPORATION LTD
MD - Shanthar Pathmanathan, Geologist - David Trabert
MD - Shanthar Pathmanathan
Geologist - David Trabert
SPONSORED BY The Market Online